Published in Curr Opin Neurol on June 01, 2007
Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies. Curr Neuropharmacol (2010) 1.10
Current and future therapies for multiple sclerosis. Scientifica (Cairo) (2013) 0.92
Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. Mediators Inflamm (2015) 0.89
Synaptic plasticity in multiple sclerosis and in experimental autoimmune encephalomyelitis. Philos Trans R Soc Lond B Biol Sci (2013) 0.87
Prognostic risk estimates of patients with multiple sclerosis and their physicians: comparison to an online analytical risk counseling tool. PLoS One (2013) 0.82
A longitudinal model for disease progression was developed and applied to multiple sclerosis. J Clin Epidemiol (2015) 0.82
The impact of slower walking speed on activities of daily living in patients with multiple sclerosis. Int J Clin Pract (2012) 0.81
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat (2013) 0.79
'You are just left to get on with it': qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis. BMJ Open (2015) 0.79
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurol Sci (2012) 0.78
No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients. BMC Neurol (2015) 0.77
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis. Neuropsychiatr Dis Treat (2015) 0.76
Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis. F1000Res (2017) 0.75
Progressive multiple sclerosis and mood disorders. Neurol Sci (2015) 0.75
Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability. Mol Neurobiol (2016) 0.75
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 2.59
Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet (2007) 2.17
Natural history of multiple sclerosis with childhood onset. N Engl J Med (2007) 1.89
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PLoS Biol (2010) 1.77
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain (2004) 1.70
First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr (2004) 1.48
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain (2010) 1.42
Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult Scler (2009) 1.41
Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol (2006) 1.40
MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain (2004) 1.31
Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol (2010) 1.28
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler (2013) 1.25
A benign form of neuromyelitis optica: does it exist? Arch Neurol (2011) 1.21
NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler (2008) 1.12
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain (2011) 1.11
Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am J Pathol (2005) 1.11
Geographic variations of multiple sclerosis in France. Brain (2010) 1.10
One can prevent post-partum MS relapses by exclusive breast feeding: no. Mult Scler (2013) 1.09
Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry (2007) 1.05
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler (2013) 1.03
Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci (2003) 1.00
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci (2010) 0.99
Uveitis associated with multiple sclerosis. Mult Scler (2008) 0.98
European validation of a standardized clinical description of multiple sclerosis. J Neurol (2004) 0.96
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol (2010) 0.93
The natural history of multiple sclerosis with childhood onset. Clin Neurol Neurosurg (2008) 0.92
Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases. Brain (2009) 0.90
Steroid hormones in multiple sclerosis. J Neurol Sci (2005) 0.89
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler (2012) 0.89
Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol (2010) 0.87
Implementation of an absolute brain 1H-MRS quantification method to assess different tissue alterations in multiple sclerosis. IEEE Trans Biomed Eng (2011) 0.87
Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry (2012) 0.87
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol (2013) 0.87
Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability. Mult Scler (2013) 0.84
Pregnancy and multiple sclerosis: the children of PRIMS. Clin Neurol Neurosurg (2006) 0.84
Primary and secondary progressive multiple sclerosis. J Neurol Sci (2003) 0.83
Correlation of diffusion and metabolic alterations in different clinical forms of multiple sclerosis. PLoS One (2012) 0.82
Tissue remodeling in periplaque regions of multiple sclerosis spinal cord lesions. Glia (2014) 0.80
"Absolute" quantification in magnetic resonance spectroscopy: validation of a clinical protocol in multiple sclerosis. Conf Proc IEEE Eng Med Biol Soc (2007) 0.79
Leukodystrophy with a cerebellar cystic aspect and intracranial atherosclerosis: an atypical presentation of cerebrotendinous xanthomatosis. J Neurol (2011) 0.79
Infections and the risk of relapse in multiple sclerosis. Brain (2002) 0.78
[Plasma exchanges in severe and acute inflammatory demyelinating attacks of the central nervous system]. Presse Med (2011) 0.77
Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications. Ther Adv Neurol Disord (2010) 0.77
[Natural history of multiple sclerosis]. Presse Med (2010) 0.76
[Central nervous system demyelinating diseases: an overview]. Presse Med (2010) 0.76
Mismatch negativity (MMN) in multiple sclerosis: an event-related potentials study in 46 patients. Clin Neurophysiol (2005) 0.76
Serum GFAP levels in optic neuropathies. J Neurol Sci (2012) 0.75
Myopathic camptocormia associated with myasthenia gravis. Clin Neurol Neurosurg (2012) 0.75
[Multiple sclerosis. What about treatment with monoclonal antibodies?]. Rev Prat (2010) 0.75
[Multiple sclerosis: positive diagnosis]. Rev Prat (2006) 0.75
[Multiple sclerosis (MS), an inflammatory or degenerative disease?]. Presse Med (2004) 0.75
[New frontiers in multiple sclerosis]. Presse Med (2007) 0.75
[Myasthenia]. Rev Prat (2005) 0.75
[Hepatitis B vaccination and multiple sclerosis]. Presse Med (2005) 0.75
[New therapies in multiple sclerosis]. Rev Prat (2012) 0.75
[Contribution of nuclear magnetic resonance imaging in multiple sclerosis]. Rev Prat (2006) 0.75
[Devic's neuromyelitis optica and related neurological disorders]. Presse Med (2010) 0.75
[Etiology of multiple sclerosis]. Rev Prat (2006) 0.75
[Cytoimmunological profile of cerebrospinal fluid in diagnosis of multiple sclerosis]. Pathol Biol (Paris) (2005) 0.75